Table 1.
Therapeutic compounds currently being investigated in clinical trials related to the treatment of cancer.
| Drug | Type of Drug |
No. of Registered Clinical Trials Related to Cancer Treatment |
Mechanism | Targeted p53 Mutants |
Phases of Clinical Trials |
Discovery |
|---|---|---|---|---|---|---|
|
APR-246
(Eprenetapopt) |
Small molecule-cysteine thiol group targeting compound | 13 | Restoration of the native conformation by binding to thiol groups in the core domain | R175H, R273H | I–III | 2002 [52] |
| COTI-2 | Zn2+ chelator | 1 | Inhibition of MUTp53 misfolding | R175H, R273H, R273C, R282W | I | 2016 [53] |
|
SAHA
(Vorinostat) |
HDAC inhibitor | 283 | Inhibition of the Hsp90 complex- induction of degradation of the mutant p53 | R249S, R273H | I–III | 2011 [54] |
| PEITC | Phytochemical | 7 | Restoration of the native conformation Oxidative stress |
R175H | I–III | 2016 [55] |